Is Your Cholesterol Test Missing the Full Picture? New…

Is Your Cholesterol Test Missing the Full Picture? New Research Highlights the Potential of ApoB Testing For decades, low-density lipoprotein cholesterol (LDL-C), often called "bad cholesterol," has been the standard blood test used to assess cardiovascular risk and guide cholesterol-lowering treatment. Millions of people undergo LDL testing every year as part of routine health screening. However, a new study published in JAMA suggests that another blood marker, apolipoprotein B (apoB), may provide a more accurate assessment of heart disease risk and help prevent more heart attacks and strokes while remaining cost-effective. The findings add to growing evidence that counting the number of harmful cholesterol particles, not just the amount of cholesterol they carry, may improve cardiovascular risk assessment. Cardiovascular disease remains the leading cause of death worldwide. One of the major contributors is the gradual buildup of cholesterol-containing plaques inside the arteries. Over time, these plaques can narrow blood vessels or rupture, increasing the risk of: Heart attack Stroke Peripheral artery disease Identifying people at higher risk allows clinicians to initiate lifestyle interventions and cholesterol-lowering medications, such as statins, before cardiovascular events occur. Traditional cholesterol testing measures LDL cholesterol (LDL-C), which estimates the amount of cholesterol carried within low-density lipoprotein particles. ApoB testing, however, measures something different. Every atherogenic (plaque-forming) lipoprotein particle, including LDL particles, contains one molecule of apolipoprotein B (apoB). Instead of measuring how much cholesterol is present, apoB measures the total number of harmful cholesterol-carrying particles circulating in the bloodstream. Researchers believe this may provide a more direct reflection of t